All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Join our
How to sequence BCMA-directed therapies in early relapsed/ refractory multiple myeloma
At the ESH 7th Translational Research Conference:
Multiple Myeloma
with Martin Kaiser, Mohamad Mohty, and Rakesh Popat
Saturday, October 5, 2024 | 09:10-10:10 CEST
Register nowThis independent educational activity is funded by GSK. All content is developed independently by the faculty. The funders are allowed no influence on the content of this activity.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
CONGRESS | @TheIACH #IACH2024 | POSTER
— Multiple Myeloma Hub (@MM_Hub) September 20, 2024
Zaineb Hasnaoui presents results from a retrospective analysis of patients with NDMM who underwent auto-HSCT.
The presentation characteristics and long-term outcomes were similar between patients aged ≤45 years and >45 years.
Follow our… pic.twitter.com/95RV7wBf9Z
CONGRESS | @TheIACH #IACH2024 | POSTER
— Multiple Myeloma Hub (@MM_Hub) September 20, 2024
Esther Ortega Vida, University Hospital of Jerez de la Frontera, shares findings from a real-world, single-center, retrospective study of the impact of novel therapies on survival in patients with MM.
Findings suggest that incorporating… pic.twitter.com/fSZpr7n4Ki
CONGRESS | @TheIACH #IACH2024 | POSTER
— Multiple Myeloma Hub (@MM_Hub) September 21, 2024
Zaineb Hasnaoui reports results from a retrospective analysis of the outcomes of patients with multiple myeloma and renal impairment who were treated with VTD triplet therapy and underwent auto-HSCT.
Survival outcomes in patients receiving… pic.twitter.com/avFcJTGZyz
CONGRESS | @TheIACH #IACH2024 | PRESENTATION
— Multiple Myeloma Hub (@MM_Hub) September 21, 2024
Thierry Facon @univ_lille provides an update on treatment for elderly patients with NDMM.
They highlight results from IMROZ and BENEFIT trials, and discuss clinical considerations and potential future directions for the treatment of… pic.twitter.com/24i8LIl47T
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox